Guías Clínicas 50 7.- Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000; 30: 125-43. 8.- Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42. 9.- Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52. 10.- World Health Organization. Secretariat. Viral hepatitis. Sixty-Third World Health Assembly A63/15. Provisional agenda item 11.12. 25 March 2010. Geneva: World Health Organization, 2010. 11.- Shepard CU, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67. 12.- Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S35-46. 13.- Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C transmission? Hepatol 2010; 52: 1497-505. 14.- Vandelli C, Renzo F, Romanò L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-upstudy. Am J Gastroenterol 2004; 99: 855-9. 15.- Puoti C, Guarisco R, Spilabotti L, et al. Should we treat VHCV carriers with normal ALT levels? The “5Ws” dilemma. J Viral Hepat 2012; 19: 229-35. 16.- Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999; 77: 801-7. 17.- Khan AJ, Luby SP, Fikree F, et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull World Health Organ 2000; 78: 956-63. 18.- Kaldor JM, Dore GJ, Correll PK. Public health challenges in hepatitis C virus infection. J Gastroenterol Hepatol 2000; 15 Suppl: E83-90. 19.- World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47. 20.- Janjua NZ, Nizamy MA.Knowledge and practices of barbers about hepatitis B and C transmission in Rawalpindi and Islamabad. J Pak Med Assoc 2004; 54: 116-9. 21.- World Health Organization. Global alert and response (GAR). Hepatitis C. Geneva: World Health Organization, 2002. Available at: http://www.who.int/csr/disease/ hepatitis/whocdscsrlyo2003/en/index4.html. 22.- Chen SL, Morgan TR. The natural history of hepatitis C virus (VHC) infection. Int J Med Sci2006; 3 (2): 47-52. 23.- Freeman AJ, Dore GJ, Law MG, et al. Estimating Guía de hepa titis c - M. Umar et al. progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16. 24.- Levine RA, Sanderson SO, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006; 4: 1271-7. 25.- Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8: 924-33. 26.- Beinhardt S, Aberle JH, Strasser M, et al. Serum level of IP-10 improves predictive value of IL28Bpolymorphisms for spontaneous clearance of acute VHC infection. Gastroenterology 2012; 142: 78-85. 27.- Vogt M, Lang T, Frösner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-70. 28.- Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26 (3 Suppl 1): S34-8. 29.- Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36 (5 Suppl 1): S30-4. 30.- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82. 31.- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55. 32.- Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-9. 33.- Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32. 34.- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65. 35.- McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93. 36.- McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92. 37.- Hamid S, Umar M, Alam A, et al. PSG consensus statement on management of hepatitis C virus Gastroenterol. latinoam 2015; Vol 26, Nº 1: 30-51
n12015
To see the actual publication please follow the link above